First‐trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell‐free DNA
Authors:
Open Access
- 8 July 2013
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (11) , 1044-1049
Abstract
Objective: This study aimed to evaluate serum‐only four‐marker first trimester (1T‐Quad) Down syndrome screening, alone or contingently to select 10–20% with highest risk for nuchal translucency (NT) or cell‐free (cf)DNA.Methods: Stored maternal serum samples (−80 °C) from 90 pregnancies with fetal Down syndrome and 1607 controls were retrieved and measured for placental growth factor, α‐fetoprotein, pregnancy‐associated plasma protein and free β‐human chorionic gonadotropin. Samples were from singleton pregnancies (9–13 + 6 weeks), and NT was measured between 11 and 13 + 6 weeks. Markers were expressed in multiples of the normal median (MoM) for gestation. Gaussian models were fitted to the distribution of log MoMs by using observed parameters, standardized maternal age distribution (mean 27, SD 5.5) and published cfDNA results.Results: The model‐predicted detection rate (DR) for 1T‐Quad was 74% [5% false‐positive rate (FPR)]. When used contingently to select for NT, the DR was 89% at 5%. When used to select for cfDNA, the DR was 91% (FPR < 0.05%).Conclusion: The 1T‐Quad test can achieve a similar DR to a second‐trimester Quad test. When used contingently to select for NT, the DR is similar to the Combined test. Used contingently to select for cfDNA would achieve even higher detection. © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markersAmerican Journal of Obstetrics and Gynecology, 2013
- Maternal serum placental growth factor and α‐fetoprotein testing in first trimester screening for Down syndromePrenatal Diagnosis, 2013
- Clinical application of massively parallel sequencing‐based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factorsPrenatal Diagnosis, 2012
- Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined, Quadruple, Serum Integrated and Integrated TestsPLOS ONE, 2012
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- Clinical utility of noninvasive fetal trisomy (NIFTY) test – early experienceThe Journal of Maternal-Fetal & Neonatal Medicine, 2012
- Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical settingAmerican Journal of Obstetrics and Gynecology, 2011
- Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity studyBMJ, 2011
- Modeling Down syndrome screening performance using first‐trimester serum markersUltrasound in Obstetrics & Gynecology, 2010
- First trimester maternal serum placental growth factor in trisomy 21 pregnanciesPrenatal Diagnosis, 2010